Innovate Alabama Supplemental Grant Program

Topeka and Shawnee County’s Small Business Incentives Program provides matching grants to local businesses to help with marketing costs, construction, equipment purchases, and more. Eligible businesses can get grants from $1,000 up to $20,000 depending on their project needs and matching investment. To qualify, businesses must be located in the City of Topeka or Shawnee County, have at least one but no more than 100 full-time employees, and demonstrate that their project will contribute to the economy.

The Southeast Overtown/Park West Community Redevelopment Agency’s (SEOPW CRA) Small Business Grant Program is a targeted financial assistance initiative designed to support the growth and stability of small businesses operating within the designated redevelopment area. With a focus on economic revitalization, job creation, and neighborhood development, the program offers direct funding to eligible local businesses to help offset operational costs, invest in infrastructure, and foster long-term sustainability. ‍ Applications are reviewed on a first-come, first-served basis and must be submitted by email or hand-delivered to the Overtown Business Resource Center located at 1490 NW 3rd Ave, Suite 106, Miami, FL 33136, or the SEOPW CRA Office located at 819 NW 2nd Ave, Third Floor, Miami, FL 33136, Tuesday–Thursday, 10 a.m. – 4 p.m.

The Food and Fiber Processing Grant Program, administered by the Farm and Food Growth Fund (FFGF) on behalf of the New York State Department of Agriculture and Markets, supports the scaling of existing and new products produced and harvested in New York State. Funding is available for the construction and renovation of facilities, as well as the purchase and installation of equipment. Priority will be given to projects that expand processing for fruits, vegetables, grains and beans for human consumption; plant and animal fibers. Eligible applicants may apply for awards ranging from $250,000 to $2.5 million. Of the $8.5 million available, $1 million is reserved for projects that use plant and animal fiber. Processed products developed through the grant must contain a minimum of 51% raw agricultural ingredients grown or raised in New York State.

This Notice of Funding Opportunity (NOFO) encourages grant applications for Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals and associated services, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The goal of projects supported by this NOFO is to provide research resources that facilitate optimization and enhancement of scientific rigor, transparency, and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP"s NIH-wide mission (https://orip.nih.gov/about-orip). This funding opportunity is designed to support both continuation of existing resources and to develop new ones when appropriate. Of special interest of the announcement is a requirement of the Center"s close coordination with efforts to develop new approach methodologies (NAMs) that complement traditional animal-based research. These include cell culture, organoids, computational models, and microphysiological systems. Applied Research Component should include studies to generate comparative data to increase applicability of NAMs and promote integration of the most predictive human disease models.

The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO which utilizes an R61/R33 phased approach.